Industry

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase II SUMMIT trial, assessing the efficacy of combined neratinib, fulvestrant, and trastuzumab in patients with hormone receptor positive, HER2-negative, HER2-mutant metastatic breast cancer, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting held in person from June 3-7 … [Read more…]

Investment will Enable Company to Scale Leading Cloud Software Suite for Intelligent Operations SANTA CLARA, Calif.–(BUSINESS WIRE)–LeanTaaS Holdings, Inc. (the “Company”), a leading provider of cloud software solutions for optimizing hospital operations and capacity management, today announced that Bain Capital Private Equity (“Bain Capital”) has acquired a majority stake in the Company from existing investors … [Read more…]

American Heart Association’s STEM Goes Red initiative gains resources to provide STEM-focused programs and mentorship for young women in the Kansas City area OVERLAND PARK, Kan.–(BUSINESS WIRE)–Today the WellSky Foundation, a nonprofit dedicated to improving quality of life for vulnerable populations, announced it has made donations totaling $100,000 to the American Heart Association® STEM Goes … [Read more…]

Company to Distribute FDA-Approved Treatment for Neuromyelitis Optica Spectrum Disorder FRISCO, Texas–(BUSINESS WIRE)–#ComplexCare—Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been named a limited distribution drug partner for ENSPRYNG® (satralizumab-mwge), manufactured by Genentech, a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines … [Read more…]

EMERYVILLE, Calif. & ALBANY, N.Y.–(BUSINESS WIRE)–#AMRI–Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, and Curia, formerly AMRI, a leading contract research, development and manufacturing organization (CDMO), today announced Curia’s adoption of The Beacon® Optofluidic system and workflows from Berkeley Lights to accelerate and expand its antibody-based drug discovery capabilities. The Beacon system … [Read more…]

In 67 ROS1 TKI-naïve patients, the confirmed objective response rate (cORR) and disease control rate (DCR) were 92.5% and 95.5%, respectively. In 38 crizotinib-pretreated patients, the cORR and DCR were 50% and 78.9%, respectively. In 12 patients with brain metastasis and measurable brain lesions at baseline, the intracranial cORR and intracranial DCR were 91.7% and … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–​ Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janet Loesberg, Pharm. D., to its Board of Directors. “I am pleased to welcome Janet as the newest director to Ambrx’s Board,” … [Read more…]

Results show broad cardiometabolic health improvement, including blood sugar control, weight loss, and medication deprescription, with half of all diabetes drugs eliminated at 5 years “Through Virta, I not only reversed my diabetes and lost over 50 pounds, I got my life back.” — Jane Ann Dimitt, who lowered her A1c from 11.4% to 5.5% … [Read more…]

— In the United States, approximately 3 out of every 4 patients do not meet target LDL-c goals1; in Europe, about 4 out of every 5 patients in the highest risk group do not meet their target LDL-c goals2 — — 82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of John Huynh, Ph.D., as the Company’s first Chief Technology Officer. Dr. Huynh brings nearly two decades of experience leading and developing specialized manufacturing … [Read more…]